Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Additional Shares
SEC Form 4 Filing
Aprea Therapeutics' CEO, Oren Gilad, recently purchased 500 shares of the company's common stock at an average price of $3.915 per share.
Summary
- On October 23, 2024, Oren Gilad, the President and CEO of Aprea Therapeutics, acquired 500 shares of common stock at a weighted average price of $3.915.
- The shares were purchased in multiple transactions with prices ranging from $3.91 to $3.92.
- Following the transaction, Gilad directly owns 333,395 shares.
- Gilad also has indirect ownership of 1,200 shares through his daughter and 600 shares through his son.
- He disclaims beneficial ownership of the shares held by his daughter and son.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of insider trading activity. The CEO buying shares is generally seen as a positive sign, but the quantity is small.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/23/2024 | Date of transaction: Oren Gilad purchased 500 shares of Aprea Therapeutics common stock. |
| 10/24/2024 | Date of signature: The Form 4 was signed on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.